«~µP¡G¹D¹Fº¸ | ³W®æ¡G18L/200L | §÷½è¡G¼í·Æªo |
²£¦a¡G¦¿Ä¬¡BÂí¦¿/·s¥[©Y |
¹D¹Fº¸FinestanÃÄ«~¯Å¥ÕÄqªo
¹D¹Fº¸ÃÄ«~¯Å¥ÕÄqªoTOTAL FINESTAN A..
À³¥Î
¥i¥Î§@»E¤A²m¤u·~ªº¥i¶ì¾¯¤Î¼ö¶ì¼u©ÊÅ骺²V©M¾¯
¥i¥Î§@ªwªj§í¨î¾¯¡B«OÅ@½¤¤Î¹«~¤u·~¤¤ªº²æ¼Ò¾¯(®Ú¾Ú¦a¤èªk³W)
¥i¥Î§@¤ÆùÛ«~¤ÎÃÄ«~¤¤ªº¦¨¤À
¾A¥Î©ó¹«~·~¾÷¥óªº¼í·Æ(°¸µM¹«~±µÄ²³õ¦X)
¨Ï¥ÎÃÄ«~¯Å¥Õªo§@¬°¹«~¥[¤u§U¾¯(ª½±µ±µÄ²)®É¡An¿í¦u¨CÓ°ê®a·í¦aªº¾A¥Îªk³W
³W®æ
FINESTANº¡¨¬¥H¤Uªk³Wªº¯Â«×n¨D¡G
FDA ,21 CFR 172-878
FDA, 21 CFR 178-3620(a)
FDA, 21 CFR 178-3570(°¸µM¹«~±µÄ²H1)
European and US pharmacopoeia
Pharmacopoeia of Japan, Germany DAB, Britain BP and France
FINAVESTAN A 360B©MFINAVESTAN A520B²Å¦XDirective 2002/72/EC
(«e90/128/ECC¤Î99/91 amendment)
Àu¶Õ
°ª«×ºë·Ò¥Õªo³Q§å·Ç¥Î©ó¶¡±µ¹«~±µÄ²(°¸µM¹«~±µÄ²)
¤£§t²¸¤ÎªÚ»ÖL¡AµL¦âµL¨ý¡A¨}¦nªº¥úéw©Ê
¥Ñ©ó¦bºë·Ò¹Lµ{¤¤ªº°ª§Þ³Nªº°ªÀ£¥[²B¤uÃÀ¡A¥»²£«~«OÃÒªº³W®æn¤ñÃĨån¨Dªº³W½d§óÄY®æ
²`¦`¥«©ô¼í¹F°Ó¶T¦³¤½¥q²£«~¥]¬A¡G¬ü§·²GÀ£ªo¡B¬ü§·¾¦½üªo¡B¬ü§·¦X¦¨ªo¡B´ßµP¦X¦¨ªo¡B
´ßµP¾¦½üªo¡B´ßµP²GÀ£ªo¡B´ßµP¼í·Æ¯×¡B¥[¼w¤h²GÀ£ªo¡B¥[¼w¤h¾¦½üªo¡BBP²GÀ£ªo¡BBP¾¦½üªo¡B
¹Å¹ê¦h¤Á«d²G¡B¹Å¹ê¦h¤Á«dªo¡BBP§Ná¾÷ªo¡B¬ü§·¤u·~¼í·Æªo¡B¬ü§·¼í·Æ¯×¡B¬ü§·§Ná¾÷ªo¡B
´ßµP§Ná¾÷ªo¡B´ßµP¾÷ªo¡B´ßµPªÅ®ðÀ£ÁY¾÷ªo¡A¹D¹Fº¸¾Éyªo¡B®J¯Á¾É¼öªo¡BºÖ´µ¨¾ùתo¡BºÖ´µ²f¤õªo¡B
§J¾|«k¼í·Æªo¡B§J¾|«k¾¦½üªo¡B§J¾|«k¼í·Æ¯×µ¥¡C
±Mª`ªA°È©ó¤u·~¡A¨Ì¦«©óÀu¨}ªº²£«~¡B¥ý¶iªº§Þ³N¡B±M·~ªº¤H¤~¡BªºªA°È¡A
¬°«È¤á´£¨Ñ¯qªººî¦X¸Ñ¨M¤è®×¡C©l²×¦p¤@ªº´£¨Ñ¥Î¤áº¡·Nªº¼í·Æªo²£«~¡Aº¡¨¬¦h¤¸¤Æªº¤£¦P»Ý¨D
²`¦`¥«©ô¼í¹F°Ó¶T¦³¤½¥q¥»¤½¥q¥N²z«~µP¤u·~¼í·Æªo¡C©ô¼í¹F§åµo¨ÑÀ³´ßµP(SHell)¡B¥[¼w¤h(CALTEX)¡B¬ü§·(Mobil)¡B®J¯Á(Esso)¡BBP¡B¹Å¹ê¦h(Casrtol)µ¥¤u·~¼í·Æªo¤Î²î²í¼í·Æªo¡C!¤@Ó¹q¸Ü¡Aµ¹±z¤@ÓÅå³ß¡C¹q¸Üq³f¦¨¥\¡A¤½¥q©Ó¿Õ§K¹B¶O,¹q¸Ü: 0755-29032325 ¶Ç¯u¡G0755-29032326
QQ:374799869 Áp«Y¤H¡G§õ¤p©j ¤â¾÷¡G 18118757667